Announcements Trials
Browse Landscape

Phase

Phase 2 65Phase 3 38Phase NA 21Phase 2/3 7Phase 1 6Phase 1/2 5Phase 4 4Phase EARLY_PHASE1 1

Status

Recruiting 5Unknown 1Active not recruiting 1

Sponsor Class

OTHER 5OTHER_GOV 1FED 1

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 7

Conditions

Prostatic Neoplasms 5Neoplasm Metastasis 2Prostate CA 1Oligometastatic Prostate Cancer 1Adenocarcinoma 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2/3 × Androgen Antagonists × Clear all
NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting
464 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT07426055 2026-03-23

PRO-BOOST-LC

Affidea Nu-med Center of Oncological DIagnostics and Therapy

Phase 2/3 Recruiting
1,200 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT07426094 2026-03-23

PRO-BOOST-N

Affidea Nu-med Center of Oncological DIagnostics and Therapy

Phase 2/3 Recruiting
1,600 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT06861192 2025-11-18

Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer

Zhongda Hospital

Phase 2/3 Recruiting
83 enrolled
Genitourinary

Prostate CA

NCT06972511 2025-05-15

Maximal Tumor Eradication for Oligometastatic Prostate Cancer

RenJi Hospital

Phase 2/3 Recruiting
120 enrolled
Genitourinary

Oligometastatic Prostate Cancer

NCT00268476 2023-04-18

STAMPEDE

Medical Research Council

Phase 2/3 Active not recruiting
11,992 enrolled
Genitourinary

Prostatic Neoplasms

NCT03879122 2022-10-26

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Spanish Oncology Genito-Urinary Group

Phase 2/3 Unknown
135 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡